Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Phase 2 Completed 43 enrolled Pfizer

RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Timeline

Start: 2006-08
Primary completion: 2010-06
Completion: 2010-06

Publications

Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther. 2013 Jul;14(7):557-63. doi: 10.4161/cbt.24598. Epub 2013 May 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral
Subject	agatolimod	Oligonucleotide (other)	0.2 mg/kg	Subcutaneous

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications